The FDA grants tentative approval for Eli Lilly ( LLY +0.5% ) and Boehringer Ingelheim's Basaglar (insulin glargine injection) as a treatment to improve glycemic control
Aug 18 (Reuters) - The U.S. Food and Drug Administration granted tentative approval for Eli Lilly and Co and Boehringer Ingelheim's insulin injection that helps control blood sugar levels in diabetes patients, Lilly said in a statement.
Aug 18 (Reuters) - The U.S. Food and Drug Administration granted tentative approval for Eli Lilly and Co and Boehringer Ingelheim's insulin injection that helps control sugar levels in diabetes patients, said Lilly in a statement.
Balanced Investing : In the season of earnings release, Eli Lilly and Company (NYSE: LLY ) has also joined the list by ..... 2014 Earnings Presentation Patent expiries have strangled Eli Lilly and Company's quarterly performance this time. This
Safety concerns linking Exubera use to lung cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products.Afrezza has demonstrated a much more favorable side-effect profile compared
pharmaceutical firm focused on antibiotic treatments. The firm's lead drug, Cubicin, was originally developed by Eli Lilly and launched in 2003 to treat Methicillin-Resistant Staphylococcus Aureus, or MRSA. Cubist acquired Adolor Corp
directors have impressive qualifications. For example, Steven Paul is a former president of Lilly Research Laboratories at Eli Lilly . Management has waived rights to sizable cash bonuses in favor of stock options, aligning pay with performance. However
basal insulin, Toujeo. The filing was also accepted by the European Medicines Agency "EMA" for EU countries. Blocking Eli Lilly US Lantus is the world's most widely prescribed insulin . The drug garnered $7.78 billion in sales revenue in the
landscape; Sanofi is poised to launch its own next-generation long-acting insulin Toujeo in the first half of 2015, and Eli Lilly could launch a biosimilar version of Lantus in the second half of 2016. We think Tresiba's prospects for beating biosimilar
By Northport Investments : Eli Lilly and Company (NYSE: LLY ) is one of our favorite major American pharmaceutical investments. In recent years, there have been